Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer

Yokoyama,Yoshihito; Futagami,Masayuki; Watanabe,Jun; Sato,Naoki; Terada,Yukihiro; Miura,Fumiharu; Sugiyama,Toru; Takano,Tadao; Yaegashi,Nobuo; Kojimahara,Takanobu; Kurachi,Hirohisa; Nishiyama,Hiroshi; Fujimori,Keiya; Tase,Toru; Mizunuma,Hideki

doi:10.3892/mco.2013.223

March-April 2014 Volume 2 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March-April 2014 Volume 2 Issue 2

Full Size Image

Article

Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer

Authors:
- Yoshihito Yokoyama
- Masayuki Futagami
- Jun Watanabe
- Naoki Sato
- Yukihiro Terada
- Fumiharu Miura
- Toru Sugiyama
- Tadao Takano
- Nobuo Yaegashi
- Takanobu Kojimahara
- Hirohisa Kurachi
- Hiroshi Nishiyama
- Keiya Fujimori
- Toru Tase
- Hideki Mizunuma
View Affiliations / Copyright

Affiliations: Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 0368562, Japan, Department of Pathologic Analysis, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 0368564, Japan, Department of Obstetrics and Gynecology, Akita University School of Medicine, Akita, Akita 0108543, Japan, Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Iwate 0208505, Japan, Department of Obstetrics and Gynecology, Tohoku University School of Medicine, Sendai, Miyagi 9808574, Japan, Department of Obstetrics and Gynecology, Yamagata University School of Medicine, Yamagata, Yamagata 9909585, Japan, Department of Obstetrics and Gynecology, Fukushima Medical University, Fukushima, Fukushima 9601295, Japan, Department of Gynecology, Miyagi Cancer Center, Natori, Miyagi 9811293, Japan
Pages: 212-218
|
Published online on: December 10, 2013

https://doi.org/10.3892/mco.2013.223
Expand metrics +

Abstract

The standard postoperative chemotherapy for epithelial ovarian cancer is a combination therapy including platinum and taxanes. The aim this study was to investigate the degree of platinum sensitivity in patients with relapsed epithelial ovarian cancer according to the treatment‑free interval (TFI) and the histological tumor type. The medical records of 405 patients diagnosed with stage III̸IV ovarian cancer, including 107 patients who relapsed after attaining a clinical complete response with first‑line treatment, were retrospectively reviewed. The degree of platinum sensitivity was assessed by comparing the progression‑free survival (PFS) following the second‑line treatment. in patients with serous̸endometrioid adenocarcinoma who were treated with platinum following relapse, there were significant differences in the PFS between the following groups of patients: those who relapsed within 6 months and those who relapsed between 6 and 12 months; those who relapsed between 6 and 12 months and those who relapsed between 12 and 18 months; and those who relapsed between 12 and 18 months and those who relapsed after 18 months. By contrast, in patients with clear cell̸mucinous adenocarcinoma who were treated with platinum following a relapse, there were no significant differences in the PFS between patients who relapsed within 6 months and those who relapsed between 6 and 12 months, while there were significant differences in the PFS between those who relapsed between 6 and 12 months and those who relapsed after 12 months. With regard to the patients who relapsed after 12 months, the PFS of those with clear cell̸mucinous adenocarcinoma was significantly shorter compared with the PFS of those with serous̸endometrioid adenocarcinoma. Therefore, we considered it justified to classify patients with clear cell̸mucinous adenocarcinoma who relapsed within 12 months as platinum‑resistant and those who relapsed after 12 months as platinum‑sensitive.

View Figures

View References

1	Ozols RF, Bundy BN, Greer BE, et al; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 21:3194–3200. 2003. View Article : Google Scholar : PubMed/NCBI
2	Burger RA, Brady MF, Bookman MA, et al: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 365:2473–2483. 2011. View Article : Google Scholar : PubMed/NCBI
3	Katsumata N, Yasuda M, Takahashi F, et al: Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 374:1331–1338. 2009. View Article : Google Scholar
4	Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 354:34–43. 2006. View Article : Google Scholar : PubMed/NCBI
5	Sugiyama T: Second-line treatment using novel chemotherapeutic and biologic agents. Cancer and Chemotherapy. 36:730–735. 2009.(In Japanese).
6	Markman M, Reichman B, Hakes T, et al: Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol. 9:1801–1805. 1991.PubMed/NCBI
7	Hoskins PJ, Le N, Gilks B, et al: Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation. J Clin Oncol. 30:1656–1662. 2012. View Article : Google Scholar
8	Gore ME, Fryatt I, Wiltshaw E, et al: Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 36:207–211. 1990. View Article : Google Scholar : PubMed/NCBI
9	Blackledge G, Lawton F, Redman C, et al: Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer. 59:650–653. 1989. View Article : Google Scholar : PubMed/NCBI
10	Harries M and Gore M: Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol. 3:537–545. 2002. View Article : Google Scholar : PubMed/NCBI
11	Parmar MK, Ledermann JA, Colombo N, et al: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 361:2099–2106. 2003. View Article : Google Scholar : PubMed/NCBI
12	Pfisterer J, Plante M, Vergote I, et al: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 24:4699–4707. 2006. View Article : Google Scholar : PubMed/NCBI
13	Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al: Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 28:3323–3329. 2010. View Article : Google Scholar : PubMed/NCBI
14	Aghajanian C, Blank SV, Goff BA, et al: OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 30:2039–2045. 2012. View Article : Google Scholar
15	McCourt C, Dessie S, Bradley AM, et al: Is there a taxane-free interval that predicts response to taxanes as a later-line treatment of recurrent ovarian or primary peritoneal cancer? Int J Gynecol Cancer. 19:343–347. 2009. View Article : Google Scholar : PubMed/NCBI
16	Rose PG, Blessing JA, Ball HG, et al: A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 88:130–135. 2003. View Article : Google Scholar : PubMed/NCBI
17	Aghajanian C, Blank SV, Goff BA, et al: OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 30:2039–2045. 2012. View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles